The effect of cigarette smoking on ovarian reserve as measured by basal serum follicle stimulating hormone (FSH) concentrations, and by the response to a standard ovarian stimulation protocol, was examined retrospectively in 173 consecutive women (108 non-smokers and 65 smokers) undergoing in-vitro fertilization (IVF) and embryo transfer treatment. Women who smoked had a higher mean basal serum FSH concentration (P ≤ 0.0001), in particular younger (<36 years) women, and required a statistically significantly higher mean dosage of gonadotrophins for ovarian stimulation than the non-smokers (48.1 ⍨ 15.6 versus 38.9 ⍨ 13.6 ampoules, 75 IU/ampoule; P < 0.0001). A lower mean number of oocytes was obtained in smokers than non-smokers (6.2 ⍨ 3.4 versus 11.1 ⍨ 6.3, oocytes P ≤ 0.0001) and the rate of abandoned cycles (18.5 versus 8.5%) and total fertilization failure (18.5 versus 8.5%) was higher. The clinical pregnancy rate per cycle in smokers was 16.9% versus 21.3% in non-smokers but this was not statistically significant. In conclusion, cigarette smoking in women appears to significantly reduce their ovarian reserve and lead to poor response to ovarian stimulation at an earlier age.
Introduction
The number of young women in the United Kingdom who smoke cigarettes continues to rise, with a recent estimate of 29% (General Household Survey, 1990) . In contrast, in the United States of America the degree of adult smoking has decreased but the decrease is less dramatic among women of reproductive age who start smoking at a younger age (US Department of Health and Human Services, 1993) . Epidemiological studies confirm that 38% of non-smokers conceive in their first cycle compared with 28% of smokers, with smokers being 3.4-fold more likely to take Ͼ1 year to conceive than non-smokers (Baird et al., 1985) . Howe et al. (1985) reported that a total of 10.7% of women who smoke Ͼ10 cigarettes 2192 © European Society for Human Reproduction and Embryology per day, compared to 5.4% of non-smokers, are involuntarily childless 5 years after stopping contraception. It has been postulated that impaired fertility and delayed conception among smoking women result from interference with gametogenesis or fertilization, failure of implantation and subclinical loss after implantation (Baird et al., 1985) . Cigarette smoking is considered a reproductive hazard to women even before they know they are pregnant, and smokers have a reduced fertility potential (Baird et al., 1985; Alderete et al., 1995) .
Conflicting reports have been published on the outcome of assisted reproduction techniques performed in women who smoke cigarettes, with some studies showing no evidence of an association between the rate of fertilization, pregnancy and smoking in young women (defined as Ͻ38 years of age) with unimpaired ovarian function (Harrison et al., 1990; Elenbogen et al., 1991; Pattinson et al., 1991; Rosevear et al., 1992; Hughes et al., 1992; Sterzik et al., 1996) . Women who smoke and have a normal ovarian reserve as assessed by the clomiphene citrate challenge test were also noted to have similar pregnancy rate to non-smokers (Sharara et al., 1994) . Parazzini and colleagues (1996) and James (1997) highlighted the relationship between smoking and an increased incidence of spontaneous dizygotic twinning in fertile women and attributed this phenomenon to high steroid hormone concentration.
A lower fertilization rate with or without a lower pregnancy rate has been reported by others (Elenenbogen et al., 1991; Rosevear et al., 1992; Rowlands et al., 1992; Van Voorhis et al., 1992; Maximovich et al., 1995) . In addition, women who smoke cigarettes have an earlier natural menopause (Jick et al., 1977) and diminished ovarian reserve (Sharara et al., 1994) .
The purpose of this retrospective study was to examine the association between cigarette smoking and basal serum follicle stimulating hormone (FSH) concentrations, the ovarian response in ovarian stimulation and outcome in 173 women undergoing in-vitro fertilization (IVF)-embryo transfer.
Materials and methods
A retrospective analysis of 173 women undergoing consecutive IVFembryo transfer cycles was conducted at the Royal Hospitals Trust Fertility Centre during the 9 month period from June 1995. Women were identified as smokers or non-smokers at interview at the time of their first consultation and the number of cigarettes smoked daily was recorded. Women requiring intracytoplasmic sperm injection (ICSI) treatment were excluded from this study. All women who entered the IVF programme had basal serum (day 2-4 of cycle) FSH and luteinizing hormone (LH) measurements as part of the routine pre-treatment assessment. Ovarian stimulation was performed in a standardized fashion, gonadotrophin releasing hormone agonist (GnRHa) being administered on day 21 of the cycle and continued until the day of human chorionic gonadotrophin (HCG) injection. Pituitary down-regulation was assessed ultrasonographically 2 weeks after the commencement of GnRHa, and human menopausal gonadotrophin (HMG) or FSH injections (150-450 IU) were begun if the endometrium was Ͻ4 mm in thickness and there was no evidence of ovarian cysts. In 6% of smokers and 4% of non-smokers a 'flare' protocol was used, the GnRHa and HMG/FSH being administered on day 1 or 2 of the cycle, if the previous ovarian response to ovarian stimulation was poor. The initial dose of HMG was individualized, typically 225 IU being given daily, and was not influenced by the smoking habit of the patient. Monitoring of the ovarian response to ovarian stimulation was by transvaginal ultrasonography (TVS) and HCG 10 000 IU was administered when three or more follicles of Ͼ18 mm were seen typically after 11 days of ovarian stimulation. Cycles were abandoned if less than three mature follicles were identified after 10 days of ovarian stimulation. Thirty five hours after HCG administration, oocyte retrieval was performed by the TVSguided technique under i.v. sedation. Fertilization was confirmed 18-24 h after in-vitro insemination by the detection of two pronuclei. A maximum of three embryos were transferred into the uterus 48-72 h after oocyte retrieval. The luteal phase was supported with progesterone pessaries 400 mg daily for 15 days. A urinary pregnancy test was then carried out and, if positive, clinical pregnancy was confirmed ultrasonographically 2-3 weeks later by detection of a gestational sac and fetal heart movement.
FSH was determined by the Kodak-Amerlex (Amersham, UK) kit calibrated against the second international reference preparation (IRP) 78/549 standard with intra-assay and interassay coefficient of variance (CV) of 4.1 and 7.9% respectively over the ranges used.
The study groups were analysed as total of cigarette smokers versus non-smokers. To reduce the influence of some of the confounding factors, we further analysed the effect of cigarette smoking in women by age interval (i) Ͻ30, 30-34, 35-39 and ജ40 years; (ii) only those undergoing their first IVF cycle.
Univariate analysis, linear regression analysis, Student's t-test or χ 2 -analysis and multivariate analysis with generalized linear modelling and logistic regression were used to determine if the differences seen were statistically significant; P Ͻ 0.05 was considered statistically significant.
Results
A total of 173 consecutive IVF cycles between June 1995 and February 1996 were analysed including 65 (37.6%) women who smoked cigarettes and 108 (62.4%) women who did not. The mean (Ϯ SD) age of those women who smoked was similar to that in women who did not (Table 1) . Ten women in this study were Ͼ39 years of age, seven (6.5%) being nonsmokers and three (4.6%) smokers. There was no difference seen with respect to the primary cause of infertility or the number of previous IVF cycles between the two groups (Table I) whether they were undergoing their first IVF cycle or not. Only three women (4.6%) were reported to smoke five or less cigarettes per day, while 24 (36.5%) smoked 10 cigarettes per day, 20 (30.8%) smoked 15 cigarettes daily and 18 (27.7%) smoked 20 or more cigarettes daily. Because the number of women who smoked Ͻ10 cigarettes daily was small, all values were pooled.
Serum basal FSH concentrations showed a wide range, 1.2-11.4 IU/l in non-smokers and 2.3-16.6 IU/l in smokers, the 2193 mean serum FSH and LH concentrations being statistically significantly higher in women who smoked when compared with those who did not (Table II) . When the data were analysed with linear regression there was no correlation seen between the number of cigarettes smoked and the basal FSH concentrations (r ϭ 0.06). A significant correlation was found between age and serum FSH concentrations (P Ͻ 0.01), which was more pronounced in the smokers (r ϭ 0.44) than non-smokers (r ϭ 0.33), (P Ͻ 0.0001) (Figure 1 ). This difference was also more apparent when the correlation was studied in women Ͻ36 years old (P Ͻ 0.01) (Figure 2) . A statistically significantly higher number of women who smoked had serum FSH concentrations of Ͼ8 IU/l compared to non-smokers (19 versus 8, P ϭ 0.0003 ).
The initial and total dose of HMG needed for ovarian stimulation was statistically significantly higher in the smokers (Table II) . In addition, the mean number of oocytes retrieved was significantly lower in the smokers than in the non-smokers (Table II) , P ഛ 0.0001.
The clinical pregnancy rate in the smokers was 16.9% (11/65), which was not statistically significantly different from that seen in the non-smokers 19.4% (21/108) (Table II ). In the pregnant women, the mean serum basal FSH was statistically significantly higher in the smokers than in the non-smokers (Table III) , but although the serum basal mean FSH concentration was lower in the pregnant group with respect to smoking status, this difference was not statistically significant (Table  III) . Age interval analysis of basal FSH concentrations again showed statistically higher values in the smokers than in the non-smokers in each sub group examined (Table IV) . Despite the statistically significantly higher mean total number of gonadotrophin ampoules required in each age subgroup, the mean number of oocytes retrieved was apparently statistically significantly lower. This difference was apparently less pronounced in the younger age group (Ͻ30 years). An analysis was not possible in the Ͼ40 year age group because of small numbers. There was no statistically significant difference seen in fertilization rates, mean total number of embryos or in the clinical pregnancy rate (Table IV) .
A total of 101 cycles were first IVF attempts (58% of total cycles); the mean age and the rates of various aetiological factors were not statistically significantly different between smokers and non-smokers (Table II) . The mean basal serum FSH concentrations were statistically significantly higher in the smokers than non-smokers in this subgroup of women (Table V) . Twelve women (36.4%) who smoked, had basal serum FSH ജ8 IU/l; this was 5-fold higher than the number of non-smoking women with similarly elevated FSH (five women, 7.4%) (P ϭ 0.001). The mean number of total gonadotrophin ampoules per cycle was higher and the number of oocytes retrieved was lower in cigarette smoking women than in non-smokers. The fertilization rate, mean total number of embryos and the clinical pregnancy rate were not seen to be statistically significantly different between the two groups (Table V) . Multivariate analyses showed similar associations and are therefore not shown in the tables. 
Discussion
The two main factors considered to be inversely related to the outcome of ovarian stimulation in assisted reproduction treatment are the woman's age and the basal serum FSH concentration. Our data suggest that cigarette smoking in infertile women undergoing assisted reproduction treatment is also adversely associated with the outcome of ovarian stimulation in IVF. We noted that women who smoke had higher serum basal FSH concentrations than non-smokers, indicating a poor ovarian reserve in these women (Jick et al., 1977; Muasher et al., 1988) . In a study by Cooper et al. (1995) , women 38-49 years old had FSH concentrations that were 66% higher among current smokers compared to ex-and nonsmokers. Both active and passive smoking have been seen to be associated with elevated FSH concentrations (Cooper et al., 1995) . We observed that although the FSH concentrations rose with age in women who smoked and those who did not, the rise was more pronounced in smokers and especially in those Ͻ36 years of age. The FSH was consistently 2 IU higher with each additional year of age, the smokers' mean FSH concentrations reaching 8 IU/l at 35-37 years (Figure 1 ), while in non-smokers this concentration was only reached after 40 years of age. Smoking has been implicated in increasing the rate of follicular atresia in women (Mattison, 1982) , and hence a rapid transition to the menopause (Jick et al., 1977; Midgette and Baron, 1990; McKinloy et al., 1992) . In the group of women studied here, this transition has been seen earlier than previously reported, as evidenced by diminished ovarian reserve and response to ovarian stimulation in infertile women undergoing IVF. It is possible that this may be due to women starting to smoke at an earlier age (US Department of Health and Human Services, 1993) and hence the increase in follicular atresia is evident sooner. Sharara et al. (1994) found an increase of up to 150% in the degree of diminished ovarian reserve in women who smoked cigarettes, when assessed by the clomiphene citrate challenge test. This study differed from ours in that they found no apparent difference in serum basal FSH concentrations between smokers and non-smokers, but this could be explained by the fact that they studied women between the ages of 35-39 years. They also reported that smoking women with a normal clomiphene citrate challenge test had outcomes similar to those of non-smokers following ovarian stimulation in an IVF programme. We observed that the range of basal FSH in pregnant women was 1.5-5.6 IU/l in non-smokers and 3.2-8.4 IU/l in smokers. By contrast we also observed a significantly higher number of smoking women with basal FSH Ͼ8 IU/l.
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Studies evaluating the impact of smoking on the response to ovarian stimulation and the outcome of assisted reproduction treatments have produced conflicting results. Our results support the argument that women who smoke require a higher dose of HMG (Hughes et al., 1994) , and have a lower number of oocytes retrieved (Elenenbogen et al., 1991; Van Voorhis et al., 1992) despite a higher HMG dose. Lower fertilization rates in smokers have been reported by several groups (Harrison et al., 1990; Elenenbogen et al., 1991; Rosevear et al., 1992; Rowlands et al., 1992) , while others found similar fertilization rates but fewer embryos because of a lower number of oocytes (Van Voorhis et al., 1992) . The number of oocytes retrieved and the fertilization rate were reported as similar in smoking and non-smoking women undergoing IVF treatment by others (Hughes et al., 1992 (Hughes et al., , 1994 Sharara et al., 1994; Sterzik et al., 1996) . These discrepancies may be due to differences in selection criteria such as the inclusion of women with normal ovarian reserve, lower age limit and different ovarian stimulation protocols. In this study the similar pregnancy rate in women who smoke and in those who do not is in agreement with other studies (Hughes et al., 1994; Sharara et al., 1994; Sterzick et al., 1996) and may be explained on the basis of the higher dosage of HMG used to achieve a better ovarian response. Thus the reduced ovarian response in smoking women could be compensated for by a higher dose of HMG needed to achieve a comparable pregnancy rate seen in nonsmokers on a lower dose of HMG. Hughes and Brennau (1996) , in a recent review that included a meta-analysis of seven comparative studies of IVF and GIFT, reported a small but clinically consistent detrimental effect of smoking in six of these studies. The review highlights many of the difficulties encountered in studies to determine the influence on fertility in general, and assisted reproduction treatments in particular, of a wide range of environmental toxins such as cigarette smoking. The authors urge further studies to determine the precise toxic effect of smoking on fertility and the benefit of short or long term cessation on women undergoing IVF treatment. A recent report by Van Voorhis et al. (1996) supports our data on the detrimental effect of smoking on ovarian function in IVF and GIFT. They noted in a retrospective study that a history of increasing tobacco exposure was associated with decreasing serum oestradiol concentrations following ovarian stimulation, number of oocytes retrieved and embryos obtained in both current and previous smokers. The pregnancy rate was lower only in current smokers, possibly indicating that even a short interval of cessation of smoking may benefit women undergoing assisted reproduction treatments.
The limitation of this study is the reliance on the accuracy of the history obtained from the women, lack of confirmation regarding their smoking habits and not considering the effect of passive smoking. Cotinine, the principal metabolite of nicotine with a half-life of~20 h, can be measured in follicular fluid to validate the women's declaration of smoking status (Rosevear et al., 1992; Hughes et al., 1994; Sterzik et al., 1996) but this was not done here. In the study by Hughes et al. (1994) , only one woman who reported that she was a non smoker had a cotinine concentration of Ͼ50 µg/l, and they also reported a strong correlation between cotinine concentrations and number of cigarettes smoked. Cotinine was considered not to provide reliable historical evidence of smoking in another study (Rowlands et al., 1992) , although the same group had previously shown that the presence of cotinine in follicular fluid was associated with a reduction in the fertilization rate (Rosevear et al., 1992) . Zenzes et al. (1996) found cotinine in follicular fluid in all active smokers and its concentration strongly correlated with the number of cigarettes smoked. A wide variation in concentrations of cotinine was noted in women who reported similar numbers of cigarettes smoked. This variation could be explained by differences in nicotine metabolism and the time from smoking to follicular fluid aspiration. Alternatively it could reflect the reliability of self-reporting, showing that although cotinine measurement is a reliable indicator of active and passive smoking, its concentration may not reflect exactly the number of cigarettes smoked. Cadmium is another toxic substance measured in follicular fluid of smokers. The follicular fluid cadmium concentration was higher in smokers than non-smokers, with a significant smoking dose-effect on its concentration (Zenzes et al., 1995) . It is possible that many metabolites of cigarettes accumulate in follicular fluid and that one or all of these may be responsible for the effects of smoking seen on ovarian function, for example by interfering with oocyte maturation (Zenzes et al., 1997) .
There is accumulating evidence to support the concept that smoking is a reproductive toxin, reducing fecundity (Bolumar et al., 1996) presumably by accelerating the diminution of ovarian reserve and hence the age of menopause. One of the questions remaining to be answered is the extent to which stopping smoking will turn the reproductive clock backward and normalize the serum basal FSH concentration. Our results suggest that this may need to be advised at an earlier age to prevent the accelerated ovarian atresia from having a significant effect on reproduction potential. Another point to be considered is the length of smoking habit and its relation to deterioration in reproductive life.
In conclusion, our results suggest a detrimental association between cigarette smoking by women and their ovarian reserve as measured by follicular phase serum FSH concentrations and their response to ovarian stimulation for IVF treatment. Their diminished ovarian response appears at an even younger age, but may be overcome by increasing the gonadotrophin dosage, provided that the basal serum FSH is within normal limits. Hence smoking may further increase the cost of ovarian stimulation drugs and this must be emphasized to the couples and purchasers of their health care.
